Skip to main content

Clinical Trial Search Results

Clinical Trial Search Results

Showing 1-9 out of 408 results.
NCT4913220

A Phase 1/2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers

Icon for trial | ACT16845 A Phase 1/2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers

This study is currently enrolling.

The purpose of the study is to determine the antitumor activity of SAR444245 for the treatment of either advanced melanoma or cutaneous squamous cell carcinoma (CSCC) when it is administered along with another anticancer therap ...

NCT03926130

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease.

Icon for trial | I6T-MC-AMAM A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease.

This study is currently enrolling.

The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research questions: How safe mirikizumab is and whether you might have any side effects when you t ...

NCT04729608

A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)

Icon for trial | AVB500-OC-004 A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)

This study is currently enrolling.

The purpose of this research study is to evaluate the safety and efficacy of an investigational drug called AVB-S6-500 combined with PAC in subjects with platinum-resistant, recurrent ovarian cancer. “Investigational” means tha ...